I’m buying dividend stocks that have been smashed by Ozempic and Wegovy

Many high-quality dividend stocks have fallen recently due to concerns over the impact of obesity drugs. Is this a buying opportunity? Ed Sheldon thinks so.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Passive income text with pin graph chart on business table

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

A lot of well-known dividend stocks have been hit by concerns over the long-term impact of weight-loss drugs. Some investors are worried these drugs (Ozempic, Wegovy, etc) are going to damage many long-standing industries.

Personally, I reckon the fears are overblown in many cases. So I’ve been snapping up a few of the beaten-up dividend stocks.

A top healthcare stock

One I’ve bought more of is healthcare company Smith & Nephew (LSE: SN.), a leading player in the joint replacement space.

I reckon the sell-off here is pretty crazy. And it seems I’m not the only one with this view.

Recently, brokerage BTIG said the impact of weight-loss drugs may prove less than feared for companies making devices for orthopaedic procedures, specifically for joint reconstruction or knee-related surgeries.

Noting that painful/stiff joints (osteoarthritis) are degenerative – and far more directly related to age – it said it sees the discussions around impact of these drugs on demand for products by such companies as “premature”.

After the recent share price fall, Smith & Nephew shares offer a lot of value, to my mind. Currently, the P/E ratio is about 12.6 and the yield is about 3.3%. I think that’s a steal.

That said, the falling share price does add some risk.

A ‘Dividend King’

Another stock I’ve bought (new to my portfolio) is the legendary Coca-Cola (NYSE: KO). It recently fell from $63 to around $52.

The theory is that weight-loss drugs are going to reduce demand for fizzy drinks. I just can’t see these drugs having a major impact on Coca-Cola though.

In my view, people are still going to drink Coke (and its other products such as Sprite and Fanta) at restaurants, bars, parties, work and home.

It’s worth noting that RBC Capital Markets analysts believe current concerns about GLP-1 drugs reaching into non-healthcare sectors may be “exaggerated”.

Doctor feedback suggests real-world compliance of the latest generation GLP-1 drugs may have its limitations“, they recently wrote.

Coca-Cola shares still aren’t cheap. Currently, the P/E ratio here is about 21. But this is a special company (a ‘Dividend King’ billing meaning it has registered 50+ consecutive dividend increases). So I’m happy to pay a higher price for it.

The current yield is about 3.3%.

An alcohol powerhouse

Finally, I’ve topped up my holding in Diageo (LSE: DGE). It’s the owner of Johnnie Walker, Tanqueray, Guinness and a stack of other well-known alcohol brands.

It seems GLP-1 drugs can also turn users off alcohol, so is a bit of a risk for Diageo.

However, again, I think the fears are probably overblown. At this stage, we don’t know how many people are going to be taking these drugs continuously (they need to be taken continuously to have the desired effects).

Meanwhile, Diageo has other things going for it. For example, it has significant exposure to emerging markets, where wealth is rising rapidly.

It also plans a focus to take tequila (the fastest-growing spirits category globally today) “around the world”.

Diageo shares currently have a P/E ratio of 18.8 and a yield of 2.7%.

I think these numbers are attractive, given the company’s incredible long-term track record when it comes to generating wealth for investors (20+ consecutive dividend increases).

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Edward Sheldon has positions in Coca-Cola, Diageo Plc, and Smith & Nephew Plc. The Motley Fool UK has recommended Diageo Plc and Smith & Nephew Plc. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Dividend Shares

Investing Articles

Here’s why I’m selling my Lloyds shares to double down on this FTSE 100 stock

Our writer digs into why he prefers HSBC over Lloyds shares right now, despite both performing really strongly in recent…

Read more »

Investing Articles

I’d invest £12,500 in this 1 stock to bag £1K of passive income!

Building a passive income stream through dividends is one of this writer’s biggest ambitions. Here’s how one stock could help.

Read more »

Young mixed-race couple sat on the beach looking out over the sea
Investing Articles

Here’s how investing £83 a week in FTSE 100 shares could make me rich

By putting less than £90 each week into FTSE 100 shares, this writer thinks he could build a portfolio worth…

Read more »

Dividend Shares

2 dividend shares with a price below £2 and a yield above 4.3%

Jon Smith applies his stock market filters for dividend shares and finds two he feels could be worthy inclusions in…

Read more »

Hand arranging wood block stacking as step stair on paper pink background
Investing Articles

690 shares in this overlooked FTSE dividend gem can make me £26,516 a year in passive income!

This FTSE heavyweight pays a 9.4% yield that can generate big passive income over time, and its shares look very…

Read more »

Investing Articles

23.5% yield! 1 of the best REITs to buy in July?

This REIT currently pays one of the highest dividend yields on the entire London Stock Exchange! Is this a warning…

Read more »

Investing Articles

Forget Rolls-Royce shares! I’d rather buy this FTSE stock

Despite Rolls-Royce (LSE: RR.) shares faring well in recent times, our writer explains why she would prefer to buy this…

Read more »

Investing Articles

Are these 2 dividend stocks no-brainer buys for a winning portfolio?

Sumayya Mansoor takes a closer look at these dividend stocks to see if they can help her build wealth through…

Read more »